Program
Inosine Monophosphate
Also written as “H5 Flu Investigational Medical Product (IMP) 1”, “GRT7040” and “IMP”.
Its studies are mostly in Osteoarthritis · Respiratory Syncytial Virus Infections · Acute Pain · Surgical Wound Infection, led by 4 companies.
Drug pageInosine Monophosphate: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 20 open or running | phase 3since Nov 11, 2015 | Nov 11, 2015 | none ahead |
| Grünenthalits history only | 11 open or running | phase 2since Sep 2, 2026 | Sep 2, 2026 | Sep 2027phase 2 · NCT07807644 |
| MB PHARMA s.r.o.its history only | 11 open or running | phase 2since Mar 13, 2024 | Mar 13, 2024 | none ahead |
| Sanofi | 11 open or running | phase 1since Mar 31, 2026 | Mar 31, 2026 | Apr 4, 2027phase 1 · NCT07516418 |
Also a collaborator on its studies: Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sanofi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 31, 2026First study: phase 1 study in Respiratory Syncytial Virus InfectionsFirst studyNCT07516418 · 360 enrolled · Australia
Ahead
- Apr 4, 2027Primary completion: phase 1 study in Respiratory Syncytial Virus InfectionsNCT07516418
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Sanofi leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07516418Respiratory Syncytial Virus Infections · Australia | 1 | Active, not recruiting | Apr 4, 2027 | 360 |
How it is read
Names in the registry
- “H5 Flu Investigational Medical Product (IMP) 1”, 1 entry
- “GRT7040”, 1 entry
- “IMP”, 1 entry
- “Investigational medical product (IMP) administered in parent study”, 1 entry
- “Investigational Medical Product (IMP) administered in parent study”, 1 entry
Conditions, from the studies’ own filings
- Osteoarthritis, 2 studies
- Respiratory Syncytial Virus Infections, 1 study
- Acute Pain, 1 study
- Surgical Wound Infection, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.